Soon Man Yoon1, Talin Haritunians, Sultan Chhina, Zhenqiu Liu, Shaohong Yang, Carol Landers, Dalin Li, Byong Duk Ye, David Shih, Eric A Vasiliauskas, Andrew Ippoliti, Shervin Rabizadeh, Stephan R Targan, Gil Y Melmed, Dermot P B McGovern. 1. *F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California; †Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea; ‡Division of Hematology and Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California; §Department of Gastroenterology and Inflammatory Bowel Disease Center, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea; and ‖Department of Pediatrics, Pediatric Inflammatory Bowel Disease Program, Cedars-Sinai Medical Center, Los Angeles, California.
Abstract
BACKGROUND: Although anti-tumor necrosis factor (TNF) agents are effective in patients with inflammatory bowel disease (IBD), many patients either do not respond to anti-TNF treatment or lose response over time. The aim of this study was to determine factors associated with response to anti-TNF therapy in IBD. METHODS: Patients with Crohn's disease (CD) or ulcerative colitis who had consented to participate in a genetics registry and been treated with anti-TNF agents were evaluated retrospectively and categorized as primary nonresponders or secondary nonresponders. We evaluated clinical, serological, and genetic characteristics associated with primary nonresponse or time to loss of response to anti-TNF agents. RESULTS: We included 314 CD (51 [16.2%] primary nonresponders and 179 [57.0%] secondary nonresponders) and 145 subjects with ulcerative colitis (43 [29.7%] primary nonresponders and 74 [51.0%] secondary nonresponders). Colonic involvement (P = 0.017; odds ratio = 8.0) and anti-TNF monotherapy (P = 0.017; odds ratio = 4.9) were associated in a multivariate analysis with primary nonresponse to anti-TNF agents in CD. In addition, higher anti-nuclear cytoplasmic antibody levels (P = 0.019; hazard ratio = 1.01) in CD, anti-nuclear cytoplasmic antibody positivity (P = 0.038; hazard ratio = 1.6) in ulcerative colitis, and a positive family history of IBD (P = 0.044; hazard ratio = 1.3) in all patients with IBD were associated with time to loss of response to anti-TNF agents. Furthermore, various known IBD susceptibility single-nucleotide polymorphisms and additional variants in immune-mediated genes were shown to be associated with primary nonresponse or time to loss of response. CONCLUSIONS: Our results may help to optimize the use of anti-TNF agents in clinical practice and position these therapies appropriately as clinicians strive for a more personalized approach to managing IBD.
BACKGROUND: Although anti-tumor necrosis factor (TNF) agents are effective in patients with inflammatory bowel disease (IBD), many patients either do not respond to anti-TNF treatment or lose response over time. The aim of this study was to determine factors associated with response to anti-TNF therapy in IBD. METHODS:Patients with Crohn's disease (CD) or ulcerative colitis who had consented to participate in a genetics registry and been treated with anti-TNF agents were evaluated retrospectively and categorized as primary nonresponders or secondary nonresponders. We evaluated clinical, serological, and genetic characteristics associated with primary nonresponse or time to loss of response to anti-TNF agents. RESULTS: We included 314 CD (51 [16.2%] primary nonresponders and 179 [57.0%] secondary nonresponders) and 145 subjects with ulcerative colitis (43 [29.7%] primary nonresponders and 74 [51.0%] secondary nonresponders). Colonic involvement (P = 0.017; odds ratio = 8.0) and anti-TNF monotherapy (P = 0.017; odds ratio = 4.9) were associated in a multivariate analysis with primary nonresponse to anti-TNF agents in CD. In addition, higher anti-nuclear cytoplasmic antibody levels (P = 0.019; hazard ratio = 1.01) in CD, anti-nuclear cytoplasmic antibody positivity (P = 0.038; hazard ratio = 1.6) in ulcerative colitis, and a positive family history of IBD (P = 0.044; hazard ratio = 1.3) in all patients with IBD were associated with time to loss of response to anti-TNF agents. Furthermore, various known IBD susceptibility single-nucleotide polymorphisms and additional variants in immune-mediated genes were shown to be associated with primary nonresponse or time to loss of response. CONCLUSIONS: Our results may help to optimize the use of anti-TNF agents in clinical practice and position these therapies appropriately as clinicians strive for a more personalized approach to managing IBD.
Authors: A Orlando; E Colombo; A Kohn; L Biancone; F Rizzello; A Viscido; R Sostegni; L Benazzato; F Castiglione; C Papi; G Meucci; G Riegler; F Mocciaro; A Cassinotti; R Cosintino; A Geremia; C Morselli; E Angelucci; A Lavagna; A Rispo; F Bossa; D Scimeca; M Cottone Journal: Dig Liver Dis Date: 2005-08 Impact factor: 4.088
Authors: Paul Rutgeerts; William J Sandborn; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Suzanne Travers; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel Journal: N Engl J Med Date: 2005-12-08 Impact factor: 91.245
Authors: Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts Journal: Lancet Date: 2002-05-04 Impact factor: 79.321
Authors: Suraj Peri; J Daniel Navarro; Troels Z Kristiansen; Ramars Amanchy; Vineeth Surendranath; Babylakshmi Muthusamy; T K B Gandhi; K N Chandrika; Nandan Deshpande; Shubha Suresh; B P Rashmi; K Shanker; N Padma; Vidya Niranjan; H C Harsha; Naveen Talreja; B M Vrushabendra; M A Ramya; A J Yatish; Mary Joy; H N Shivashankar; M P Kavitha; Minal Menezes; Dipanwita Roy Choudhury; Neelanjana Ghosh; R Saravana; Sreenath Chandran; Sujatha Mohan; Chandra Kiran Jonnalagadda; C K Prasad; Chandan Kumar-Sinha; Krishna S Deshpande; Akhilesh Pandey Journal: Nucleic Acids Res Date: 2004-01-01 Impact factor: 16.971
Authors: William S Mow; Eric A Vasiliauskas; Ying-Chao Lin; Phillip R Fleshner; Konstantinos A Papadakis; Kent D Taylor; Carol J Landers; Maria T Abreu-Martin; Jerome I Rotter; Huiying Yang; Stephan R Targan Journal: Gastroenterology Date: 2004-02 Impact factor: 22.682
Authors: Wei Li; Qing Zhang; Naoki Oiso; Edward K Novak; Rashi Gautam; Edward P O'Brien; Caroline L Tinsley; Derek J Blake; Richard A Spritz; Neal G Copeland; Nancy A Jenkins; Dominick Amato; Bruce A Roe; Marta Starcevic; Esteban C Dell'Angelica; Rosemary W Elliott; Vishnu Mishra; Stephen F Kingsmore; Richard E Paylor; Richard T Swank Journal: Nat Genet Date: 2003-08-17 Impact factor: 38.330
Authors: Mirna Šimurina; Noortje de Haan; Frano Vučković; Nicholas A Kennedy; Jerko Štambuk; David Falck; Irena Trbojević-Akmačić; Florent Clerc; Genadij Razdorov; Anna Khon; Anna Latiano; Renata D'Incà; Silvio Danese; Stephan Targan; Carol Landers; Marla Dubinsky; Dermot P B McGovern; Vito Annese; Manfred Wuhrer; Gordan Lauc Journal: Gastroenterology Date: 2018-01-06 Impact factor: 22.682
Authors: Alka A Potdar; Dalin Li; Talin Haritunians; Kelli L VanDussen; Marie F Fiorino; Ta-Chiang Liu; Thaddeus S Stappenbeck; Phillip Fleshner; Stephan R Targan; Dermot P B McGovern; Janine Bilsborough Journal: J Crohns Colitis Date: 2019-08-14 Impact factor: 9.071
Authors: Kristin E Burke; Hamed Khalili; John J Garber; Talin Haritunians; Dermot P B McGovern; Ramnik J Xavier; Ashwin N Ananthakrishnan Journal: Inflamm Bowel Dis Date: 2018-07-12 Impact factor: 5.325